Global Chronic Plaque Psoriasis Market to Grow with Advances in Biologics and Personalized Medicine – BIS Research

What is Chronic Plaque Psoriasis? 

Chronic plaque psoriasis is a chronic, immune-mediated inflammatory skin condition that affects 2–3% of the global population. It is characterized by red, scaly plaques resulting from accelerated skin cell turnover and immune dysregulation. The disease is strongly associated with autoimmunity, obesity, and genetic predisposition, and often has significant psychological and social impacts. Treatment ranges from topical corticosteroids and systemic agents to advanced biologics and immunotherapies for severe cases. 

What is the Current Market Outlook for Chronic Plaque Psoriasis? 

North America and Europe lead the psoriasis market due to widespread biologic adoption, structured reimbursement systems, and advanced dermatology care networks. Asia-Pacific is emerging as a high-growth region, supported by rising disease awareness, healthcare infrastructure development, and gradual reimbursement improvements. Barriers remain, particularly the high cost of biologics, patient adherence challenges, and limited awareness in low-income regions. According to BIS Research, chronic plaque psoriasis market is set to grow significantly in upcoming years. 

What is the key Innovation & Trends in Chronic Plaque Psoriasis Market? 

• Rapid uptake of IL-17 and IL-23 inhibitors for moderate to severe psoriasis 
• Growing role of personalized medicine and genetic profiling for treatment selection 
• Adoption of AI-based imaging and digital health platforms for disease monitoring 
• Expansion of combination therapies to improve disease control and reduce relapse 
• Improved focus on quality of life and mental health alongside clinical outcomes 
• Strategic partnerships to develop biomarkers and companion diagnostics 

How Does This Report Help Organizations Drive Strategic Growth? 

• Benchmark drug classes – Compare IL-17, IL-23, PDE4 inhibitors, TNF-alpha inhibitors, and topical steroids. 
• Evaluate innovation pipelines – Track biologics, biosimilars, biomarkers, and combination regimens. 
• Identify regional opportunities – Assess adoption trends across North America, Europe, Asia-Pacific, and RoW. 
• Monitor strategies – Review M&A, partnerships, and digital health collaborations. 
• Navigate barriers – Address biologic cost, patient adherence, and treatment access challenges. 

Explore Full TOC or Book a Preview  

What Are the Demand Driver and Challenges in Chronic Plaque Psoriasis Market? 

Drivers 

• Rising global prevalence of psoriasis and autoimmune diseases 
• High demand for biologic therapies in moderate to severe disease 
• Advances in diagnostic tools, AI imaging, and telemedicine 
• Increasing use of precision medicine and biomarker-guided treatment 
• Expanding reimbursement for biologics in developed markets 

Challenges 

• High cost of biologic therapies limiting access in some regions 
• Adherence challenges with long-term systemic or biologic use 
• Lack of awareness and delayed diagnosis in underserved regions 
• Persistent side effect concerns with ADT, systemic agents, and immunotherapies 

What is the Market Segmentation in the Chronic Plaque Psoriasis Market? 

By Drug Class 

• Interleukin (IL)-17A Inhibitors 
• Interleukin (IL)-23 Inhibitors 
• Phosphodiesterase 4 (PDE4) Inhibitors 
• Topical Steroids 
• Tumor Necrosis Factor (TNF)-Alpha Inhibitors 

By Region 

• North America 
• Europe 
• Asia-Pacific 
• Rest of the World 

What Is the Competitive Landscape in the Chronic Plaque Psoriasis Market? 

Strategic Initiatives 

Novartis, AbbVie, and Janssen are expanding portfolios with next-gen IL-17 and IL-23 inhibitors, while Eli Lilly and Amgen invest in biosimilars and combination regimens. Pharma firms are partnering with digital health startups to integrate AI-based imaging and mobile monitoring apps, supporting personalized care and adherence. 

Here Are Some Case Studies and Success Stories in Chronic Plaque Psoriasis Market 

In the U.S., Skyrizi and Cosentyx showed strong real-world uptake, improving long-term disease control in moderate-to-severe psoriasis. In Europe, AI-based imaging tools were piloted in dermatology clinics, enhancing lesion severity assessment and treatment optimization. In Asia-Pacific, biomarker-guided programs in Japan and Korea supported tailored biologic selection, improving outcomes and reducing relapse rates. 

[Schedule a Call with Industry Experts] 

[Download Complete TOC] 

Related Reports from BIS Research 

Barrett’s Esophagus Market                     

Metastatic Prostate Cancer Market             

Non-Metastatic Prostate Cancer Market                        

About BIS Research 

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.   

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.    

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.   

Contact 

Head of Marketing   

Email: media@bisresearch.com    

BIS Research Inc.   

39111 PASEO PADRE PKWY STE 313,   

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights   

Get Expert Insights @https://community.insightmonk.com    

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research    

Connect with us on Twitter@ https://twitter.com/BISResearch 

Connect with us on Medium@ https://medium.com/@faisal.bis 

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc